NEXAVAR is contraindicated in patients with known severe hypersensitivity to sorafenib or any other component of NEXAVAR. Continue reading below

Resources and Financial Support

Additional support, within REACH®

Nexavar (sorafenib) Homepage Image Text

Resources for Expert Assistance and Care Helpline (REACH) is a free support program available to eligible patients who have been prescribed Nexavar. REACH provides patients with information about their therapy, helps them evaluate their financial assistance options, and offers education to healthcare professionals.

Reach Financial Assistance Logo Reach Financial Assistance Logo
Dispensing Pharmacy Reach Form Dispensing Pharmacy Reach Form

Getting Approved and Getting Medication

Call REACH Service Counselors for:

  • $0 Co-Pay* Assistance for privately insured patients
  • Benefit verification/prior authorization denial and appeal information
  • Coordination with Specialty Pharmacy Providers (SPP), self-dispensing practices, and outpatient pharmacies
  • Alternate coverage research for the uninsured and underinsured
  • Referral of qualified patients to charitable organizations for assistance with their out-of-pocket expenses
  • Information on Medicare Part D plan
  • Medicaid application and enrollment information

Access to Education and Support

Call REACH Nurse Counselors for:

  • Patient education materials
    • Patient starter kits
    • Refill reminders
  • Education on adverse event management
  • Answers to questions for patients and caregivers

Enroll Your Patients in REACH

To enroll your patients in REACH:

  • Fill out the REACH enrollment forms
  • Sign the form in the space provided under "Physician Declaration"
  • Have your patient sign the form in the space provided under "Patient Authorization"
  • Fax both pages of the form to 1-866-639-5181

To access free assistance and support:

  • You, the pharmacy, or your patients can call the REACH program at 1-866-639-2827

*Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the co-payment support provided under this program, e.g., co-pay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payors of any benefits they receive and the value of this program, as required by contract or otherwise. Void where prohibited by law, taxed, or restricted. Patients enrolled in Bayer’s Patient Assistance Program are not eligible. Bayer may determine eligibility, monitor participation, equitably distribute product, and modify or discontinue any aspect of the REACH program at any time, including but not limited to this commercial co-pay assistance program.

REACH offers referrals to third party organizations; eligibility criteria apply.


NEXAVAR is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC).

NEXAVAR is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Important Safety Information

For important risk and use information about NEXAVAR, please see the full Prescribing Information.


For important risk and use information about STIVARGA, please see the full Prescribing Information including the Boxed Warning.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.